Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on May 07, 2021 11:09am
99 Views
Post# 33152157

RE:RE:RE:As usual

RE:RE:RE:As usual

At the time when institutional investors reduced their participation in trading activities in FY21, retail investors turned aggressive and their market share rose sharply to 45% amid rising uncertainty over the Covid-19 pandemic. In simple words, it means that if the average daily trading volume on the exchange is Rs 70,000 crore then nearly half of that is traded by individual investors.

 

 

Why is retail participation is on the rise?

There are multiple reasons for the rise of retail investors in the market. Niteen S Dharmawat, co-founder, Aurum Capital, said: “The most important is the relatively poor returns by other assets and lower interest rates on bank deposits. Many of the investors have come for the first time. This coupled with technological proliferation provided very easy access to the market to people seating at home during the pandemic.”

Besides, the significant rise in the share of individual investors in FY21 can be attributed to the increase in new investor registrations witnessed in 2020-2021.

G Chokkalingam, founder, Equinomics Research and Advisory said, “Firstly, individual investors were attracted by the cheap valuation of stocks post March 2020 crash. Later, two crore new retail investors entered the market when they saw a massive rally in midcaps and smallcaps. They are continuously buying stocks. Roughly, one lakh new investors are getting registered in equity markets every day from the start of 2021.”

 

Top sectoral exposure

Sectors like trading, finance, IT, textile, pharmaceutical, construction and engineering are among the favourites of individual investors including high networth investors. On the other hand, they have minimum holdings in sectors like ports, e-commerce, courier and insurance, among others.

 

https://www.money9.com/news/markets/market-news/individual-investors-are-now-big-bulls-of-indian-equity-markets-with-nearly-50-trading-volume-33749.html

 

 

<< Previous
Bullboard Posts
Next >>